Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort

被引：7

作者：

Vukotic, R. ^{[1
]}

Di Donato, R. ^{[1
]}

Conti, F. ^{[1
]}

Scuteri, A. ^{[1
]}

Serra, C. ^{[2
]}

Andreone, P. ^{[1
]}

机构：

[1] Univ Bologna, Dipartimento Sci Med & Chirurg, Ctr Ric Studio Epatiti, Bologna, Italy

[2] Azienda Osped Univ Bologna, Dipartimento Insufficienze Organo & Trapianti, Policlin S Orsola Malpighi, Bologna, Italy

来源：

JOURNAL OF VIRAL HEPATITIS | 2017年 / 24卷 / 01期

关键词：

direct-acting antivirals; hepatitis C virus; hepatocellular carcinoma; pegylated interferon; prophylaxis; RECURRENCE; HCC; THERAPY; RESECTION; RISK;

D O I：

10.1111/jvh.12651

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

During the past two decades, several studies showed reduced rates of hepatocellular carcinoma recurrence in patients with HCV-related cirrhosis after interferon-based antiviral therapies respect to untreated controls, even without reaching viral clearance. The recent development of new all-oral regimens with direct-acting antivirals has radically improved the therapeutic management of hepatitis C. Nevertheless, paradoxical, or at least unexpected, high rates of both occurrence and recurrence of hepatocellular carcinoma after a treatment with direct-acting antivirals, have been reported in the recent literature. These findings generated a strong rebound in the hepatology community and are at present still controversial. We sought to compare the hepatocellular carcinoma recurrence-free survival of a historical cohort treated with pegylated interferon/ribavirin and an untreated cohort with a cohort treated with direct-acting antivirals.

引用

页码：13 / 16

页数：4

共 50 条

[31] Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma
Pinero, Federico
Mendizabal, Manuel
Ridruejo, Ezequiel
Wolff, Fernando Herz
Ameigeiras, Beatriz
Anders, Margarita
Schinoni, Maria Isabel
Reggiardo, Virginia
Palazzo, Ana
Videla, Maria
Alonso, Cristina
Santos, Luisa
Varon, Adriana
Figueroa, Sebastian
Vistarini, Cecilia
Adrover, Raul
Fernandez, Nora
Perez, Daniela
Tanno, Federico
Hernandez, Nelia
Sixto, Marcela
Borzi, Silvia
Bruno, Andres
Cocozzella, Daniel
Soza, Alejandro
Descalzi, Valeria
Estepo, Claudio
Zerega, Alina
de Araujo, Alexandre
Cheinquer, Hugo
Silva, Marcelo
Barreyro, F.
Billordo, A.
Caballini, P.
Carbonetti, R.
Ceballos, S.
Deltrozzo, V
Gadea, C.
Garraztazul, P.
Garrocho, C.
Manero, E.
Mendoza, C.
Mengarelli, S.
Moreno, V
Peralta, M.
Ratusnu, N.
Romero, G.
Ruf, A.
Tanno, M.
Tanno, F.
LIVER INTERNATIONAL, 2019, 39 (06) : 1033 - 1043
[32] Direct-acting antivirals and the risk of hepatocellular carcinoma: The end of a polemic?
Pol, Stanislas
Vallet-Pichard, Anais
Fontaine, Helene
Carrat, Fabrice
LIVER INTERNATIONAL, 2019, 39 (03) : 446 - 447
[33] Surgical outcomes for hepatocellular carcinoma detected after hepatitis C virus eradiation by direct-acting antivirals
Tanaka, Shogo
Shinkawa, Hiroji
Tamori, Akihiro
Takemura, Shigekazu
Takahashi, Shinji
Amano, Ryosuke
Kimura, Kenjiro
Ohira, Go
Kawada, Norifumi
Kubo, Shoji
JOURNAL OF SURGICAL ONCOLOGY, 2020, 122 (08) : 1543 - 1552
[34] Patients with HIV and cirrhosis: the risk for hepatocellular carcinoma after direct-acting antivirals for hepatitis C virus
Guardigni, Viola
Toschi, Alice
Badia, Lorenzo
Del Turco, Elena Rosselli
Salsi, Eleonora
Cristini, Francesco
Sighinolfi, Laura
Fabbri, Gabriele
Massari, Marco
Cuomo, Gianluca
Viale, Pierluigi
Verucchi, Gabriella
AIDS, 2021, 35 (12) : 1967 - 1972
[35] Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
Kishta, Sara
Tabll, Ashraf
Kolaric, Tea Omanovic
Smolic, Robert
Smolic, Martina
BIOMEDICINES, 2020, 8 (06) : 1 - 15
[36] Impact of viral eradication by direct-acting antivirals on clinical outcomes after curative treatment for hepatitis C virus-associated hepatocellular carcinoma
Nagaoki, Yuko
Yamaoka, Kenji
Fujii, Yasutoshi
Uchikawa, Shinsuke
Fujino, Hatsue
Ono, Atsushi
Murakami, Eisuke
Kawaoka, Tomokazu
Miki, Daiki
Aikata, Hiroshi
Hayes, Clair Nelson
Tsuge, Masataka
Oka, Shiro
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2025, 18
[37] Survival and recurrence rates of hepatocellular carcinoma after treatment of chronic hepatitis C using direct acting antivirals
Lithy, Rania M.
Elbaz, Tamer
Abdelmaksoud, Ahmed H.
Nabil, Mohamed M.
Rashed, Noha
Omran, Dalia
Kaseb, Ahmed O.
Abdelaziz, Ashraf O.
Shousha, Hend, I
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (02) : 227 - 234
[38] Direct-acting antiviral treatment for patients with hepatocellular carcinoma
Kushner, Tatyana
Dieterich, Douglas
Saberi, Behnam
CURRENT OPINION IN GASTROENTEROLOGY, 2018, 34 (03) : 132 - 139
[39] Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation
Turgeon, Michael K.
Shah, Shimul A.
Delman, Aaron M.
Tran, Benjamin, V
Agopian, Vatche G.
Wedd, Joel P.
Magliocca, Joseph F.
Kim, Ahyoung
Cameron, Andrew
Olyaei, Ali
Orloff, Susan L.
Anderson, Matthew P.
Kubal, Chandrashekhar A.
Cannon, Robert M.
Locke, Jayme E.
Simpson, Mary A.
Akoad, Mohamed E.
Wongjirad, Chelsey P.
Emamaullee, Juliet
Moro, Amika
Aucejo, Federico
Feizpour, Cyrus A.
Vagefi, Parsia A.
Nguyen, Mindie H.
Esquivel, Carlos O.
Dhanireddy, Kiran
Subramanian, Vijay
Chavarriaga, Alejandro
Kazimi, Marwan M.
Anderson, Maia S.
Sonnenday, Christopher J.
Kim, Steven C.
Foley, David P.
Abdouljoud, Marwan
Salgia, Reena J.
Moris, Dimitrios
Sudan, Debra L.
Ganesh, Swaytha R.
Humar, Abhinav
Doyle, Majella
Chapman, William C.
Maithel, Shishir K.
ANNALS OF SURGERY, 2021, 274 (04) : 613 - 620
[40] Increased incidence or recurrence of hepatocellular carcinoma in hepatitis C virus cirrhotic patients treated with direct-acting antivirals: myth or fact?
Maida, Marcello
Cabibbo, Giuseppe
Camma, Calogero
EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (04) : 307 - 309

← 1 2 3 4 5 →